GO:0002153 steroid receptor RNA activator RNA binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002153 defines the molecular function of binding to the steroid receptor RNA activator RNA (SRA), a long non-coding RNA that enhances steroid hormone receptor transcriptional activity indirectly, without direct SRA-steroid receptor binding.
• SRA functions as a nuclear receptor coregulator with multiple protein partners, including steroid receptors, p68, and other RNA-binding proteins.
• SRA RNA is subject to post-transcriptional modification, such as pseudouridylation by hPus1p, which affects its RNA binding properties.
• SRA is implicated in human diseases including endometrial cancer, polycystic ovary syndrome, and erythroblast transcriptional regulation.
• The SRA locus also encodes a protein isoform (SRAP) that may interact with SRA RNA, adding complexity to its functional roles.
• Studying GO:0002153 requires integrated approaches such as RNA immunoprecipitation, CRISPR knockout of SRA, and transcriptomic profiling.
Description
GO:0002153, steroid receptor RNA activator RNA binding, is a molecular function term describing the binding of proteins or other molecules to the steroid receptor RNA activator (SRA) RNA. SRA is a long non-coding RNA that acts as a transcriptional coactivator for steroid hormone receptors and other nuclear receptors, enhancing their activity through indirect mechanisms that do not involve direct binding of SRA to the receptor. This function is critical for understanding how non-coding RNAs modulate gene expression in hormone-responsive tissues and in diseases such as cancer and metabolic disorders. Researchers study this term to identify RNA-binding proteins that interact with SRA, to map the structural determinants of these interactions, and to explore how perturbations affect downstream transcriptional programs. The SRA RNA itself is subject to modifications, such as pseudouridylation, which can influence its binding affinity and functional output. Given its broad impact on nuclear receptor signaling, GO:0002153 represents a key node in the interface between non-coding RNA biology and transcriptional regulation.
steroid receptor RNA activator RNA binding At A Glance
| GO ID | GO:0002153 |
|---|---|
| GO term | steroid receptor RNA activator RNA binding |
| Ontology | molecular_function |
| Synonym | SRA binding |
| Definition | Binding to a steroid receptor RNA activator RNA (SRA). SRA enhances steroid hormone receptor transcriptional activity as an RNA transcript by an indirect mechanism that does not involve SRA-steroid receptor binding. |
| Major function | Mediates the interaction of proteins with SRA lncRNA to modulate nuclear receptor transcriptional activity. |
| Related RNA | Steroid receptor RNA activator (SRA), a long non-coding RNA. |
| Key partners | Steroid hormone receptors, p68 (DDX5), hPus1p, and other RNA-binding proteins. |
| Disease relevance | Implicated in endometrial cancer, polycystic ovary syndrome, and erythroblast regulation. |
What Is GO:0002153?
In our own words, GO:0002153 describes the molecular function of selectively binding to the steroid receptor RNA activator RNA (SRA). SRA is a long non-coding RNA that boosts the transcriptional activity of steroid hormone receptors and other nuclear receptors via an indirect mechanism that does not require SRA to physically bind the receptor itself. This binding function is performed by proteins that recognize SRA RNA and mediate its coregulatory effects.
Why Is steroid receptor RNA activator RNA binding Important in Cell Biology?
Understanding GO:0002153 is essential because SRA-mediated RNA binding represents a paradigm for how long non-coding RNAs can act as molecular scaffolds to assemble transcriptional coregulator complexes. This function impacts hormone signaling, cell proliferation, and differentiation, and its dysregulation is linked to cancer and metabolic disorders. Moreover, the indirect mechanism of SRA action highlights the diversity of RNA-protein interactions in gene regulation.
• SRA RNA binding is a key step in nuclear receptor coactivation, influencing hormone-responsive gene expression.
• Dysregulation of SRA and its binding partners is associated with endometrial cancer progression via Wnt/β-catenin signaling.
• Silencing SRA attenuates polycystic ovary syndrome in mouse models, suggesting therapeutic potential.
• SRA is involved in genome-wide transcriptional regulation in human erythroblasts, linking it to blood cell development.
• Post-transcriptional modification of SRA by hPus1p affects its RNA binding and activity, adding a regulatory layer.
• The SRA locus encodes both non-coding RNA and a protein isoform (SRAP), which may interact and complicate functional studies.
• SRA interacts with the DEAD-box RNA-binding protein p68 to mediate CTCF transcriptional insulation.
• The thyroid hormone receptor contains an RNA-binding domain that enhances transcriptional activation, paralleling SRA mechanisms.
• GO:0002153 provides a molecular handle to dissect lncRNA-protein interactions in transcription.
• Targeting SRA binding may offer new strategies for modulating hormone-dependent diseases.
Molecular Mechanism of steroid receptor RNA activator RNA binding
Recognition of SRA RNA by RNA-binding proteins
In simple terms: Proteins that bind SRA RNA recognize specific sequences or structures on the RNA.
SRA RNA contains structural elements that are recognized by RNA-binding proteins such as p68 (DDX5) and hPus1p. The binding is sequence- and structure-specific, and it can be modulated by RNA modifications. This recognition is the first step in assembling a functional coregulator complex.
Indirect enhancement of steroid receptor activity
In simple terms: SRA boosts steroid receptor activity without directly touching the receptor.
SRA enhances steroid hormone receptor transcriptional activity as an RNA transcript by an indirect mechanism that does not involve SRA-steroid receptor binding. Instead, SRA likely acts as a scaffold to recruit coregulatory proteins that then modulate receptor function. This indirect action distinguishes SRA from classical coactivators.
Role of RNA modifications in SRA binding
In simple terms: Chemical changes to SRA RNA can affect how proteins bind to it.
The human pseudouridine synthase 1 (hPus1p) modifies SRA RNA by pseudouridylation, which can alter its RNA binding properties and activity. Such modifications add a layer of regulation to GO:0002153, influencing which proteins bind and how strongly.
Integration with chromatin and transcription machinery
In simple terms: SRA binding helps connect RNA to the machinery that controls gene expression.
SRA interacts with p68 and CTCF to mediate transcriptional insulation, demonstrating its integration with chromatin architecture. This suggests that SRA RNA binding is not isolated but part of larger transcriptional regulatory networks. The thyroid hormone receptor also contains an RNA-binding domain that enhances transcriptional activation, providing a parallel example.
Key Genes Involved in GO:0002153 steroid receptor RNA activator RNA binding
The following genes and proteins are central to the study of steroid receptor RNA activator RNA binding (GO:0002153).
| Gene | Major Role | Research Relevance |
|---|---|---|
| SRA1 | Encodes the SRA long non-coding RNA and the SRAP protein isoform | Core RNA component for GO:0002153; implicated in cancer and PCOS |
| DDX5 (p68) | DEAD-box RNA helicase that binds SRA RNA | Mediates CTCF transcriptional insulation and nuclear receptor coactivation |
| PUS1 | Pseudouridine synthase that modifies SRA RNA | Regulates SRA RNA binding and activity via pseudouridylation |
| ESR1 | Estrogen receptor alpha, a steroid hormone receptor | Target of SRA coactivation; relevant to breast and endometrial cancer |
| ESR2 | Estrogen receptor beta | Another nuclear receptor potentially modulated by SRA |
| AR | Androgen receptor | Steroid receptor whose activity may be influenced by SRA |
| PGR | Progesterone receptor | Steroid receptor linked to SRA coactivation |
| THRA | Thyroid hormone receptor alpha | Contains an RNA-binding domain that enhances transcriptional activation |
| THRB | Thyroid hormone receptor beta | Similar to THRA, may interact with RNA to modulate transcription |
| CTCF | Chromatin insulator protein | Cooperates with SRA and p68 for transcriptional insulation |
| SRAP | Protein isoform encoded by SRA1 | Proposed partner of SRA noncoding RNA; may modulate its function |
| WNT4 | Wnt signaling component | SRA promotes endometrial cancer via Wnt/β-catenin pathway |
| CTNNB1 | Beta-catenin | Effector of Wnt signaling activated by SRA in cancer |
| CDKN1A | Cell cycle inhibitor p21 | Potential downstream target of SRA-mediated transcription |
| MYC | Oncogene | May be regulated by SRA-associated transcriptional complexes |
| GATA1 | Erythroid transcription factor | SRA regulates genome-wide transcription in erythroblasts |
| KLF1 | Erythroid transcription factor | Potential target of SRA in erythroblasts |
| HBB | Beta-globin | Erythroid gene potentially regulated by SRA |
How Is steroid receptor RNA activator RNA binding Regulated?
The function of GO:0002153 is regulated at multiple levels. RNA modifications such as pseudouridylation by hPus1p can alter SRA RNA structure and its binding to proteins. The availability of binding partners like p68 and steroid receptors also modulates the interaction. Additionally, SRA RNA levels themselves are transcriptionally regulated, as shown by genome-wide studies in erythroblasts. Hormonal signals may further influence the assembly of SRA-containing complexes.
steroid receptor RNA activator RNA binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SRA1 | Endometrial cancer | SRA knockout in endometrial cancer cell lines (e.g., Ishikawa) |
| SRA1 | Polycystic ovary syndrome | SRA silencing in mouse models of PCOS |
| SRA1 | Erythroid development | SRA knockout in human erythroblast cultures |
| DDX5 | Cancer and transcriptional regulation | DDX5 knockout or point mutation in cancer cells |
| PUS1 | RNA modification disorders | PUS1 knockout or overexpression in cell lines |
Endometrial cancer
SRA promotes the progression of endometrial cancer via the Wnt/β-catenin signaling pathway. Knockdown of SRA reduces tumor growth, suggesting that SRA RNA binding is a potential therapeutic target. The interaction of SRA with proteins that modulate Wnt signaling may be critical for its oncogenic effects.
Polycystic ovary syndrome (PCOS)
Silencing of the long non-coding RNA SRA attenuates polycystic ovary syndrome in mice. This indicates that SRA RNA binding and its downstream effects contribute to PCOS pathogenesis. Targeting SRA or its binding partners could offer new treatments for PCOS.
Erythroid disorders
SRA is involved in genome-wide transcriptional regulation in human erythroblasts. Dysregulation of SRA-mediated RNA binding may affect red blood cell development and contribute to erythroid disorders. Understanding these interactions could inform therapies for anemias.
From steroid receptor RNA activator RNA binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SRA RNA binding to p68 affect transcriptional insulation? | Knockout of DDX5 or SRA in HEK293T cells followed by reporter assays |
| How does pseudouridylation of SRA affect its function? | Point mutation of PUS1 catalytic residues or SRA modification sites |
| Can SRA knockdown inhibit endometrial cancer growth? | SRA knockout in endometrial cancer cell lines and xenograft models |
| What is the role of SRA in erythroid differentiation? | Knockout of SRA in human CD34+ hematopoietic stem cells |
| Does SRAP protein interact with SRA RNA? | Knock-in of tagged SRAP in cell lines |
| Can overexpression of SRA enhance steroid receptor activity? | Overexpression of SRA in hormone-responsive cell lines |
How to Study the steroid receptor RNA activator RNA binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA immunoprecipitation (RIP) | Binding of proteins to SRA RNA | Identify novel SRA-binding proteins |
| CRISPR knockout + RNA-seq | Transcriptional changes upon loss of SRA | Elucidate SRA-dependent pathways |
| Pseudouridylation detection | RNA modification status of SRA | Study PUS1-mediated regulation |
| Reporter assays | Steroid receptor transcriptional activity | Test SRA coactivation function |
| Xenograft models | Tumor growth in vivo | Evaluate SRA as therapeutic target |
| Electrophoretic mobility shift assay (EMSA) | Direct RNA-protein binding | Confirm SRA-protein interactions |
| Proteomics (e.g., BioID) | Proximity-dependent labeling of SRA-associated proteins | Map SRA interactome |
| Single-molecule imaging | Real-time dynamics of SRA binding | Visualize interactions in live cells |
RNA immunoprecipitation (RIP)
RIP using antibodies against candidate RNA-binding proteins (e.g., p68) followed by RT-qPCR or sequencing can identify SRA RNA interactions. This method directly tests GO:0002153 by measuring binding in vivo.
CRISPR knockout and transcriptomics
Knocking out SRA or its binding partners followed by RNA-seq reveals downstream transcriptional changes. This approach links the binding function to cellular phenotypes.
Pseudouridylation assays
Detection of pseudouridine in SRA RNA using site-specific methods or mass spectrometry can assess the impact of PUS1 on SRA modification. This helps understand how RNA modifications regulate binding.
Structural studies
NMR or crystallography of RNA-binding domains in complex with SRA RNA fragments can provide atomic details of the interaction. Such studies inform the design of inhibitors.
How CRISPR Can Be Used to Study GO:0002153 steroid receptor RNA activator RNA binding
Knockout
CRISPR knockout of SRA1 or its binding partners (e.g., DDX5, PUS1) can abolish SRA RNA binding and reveal loss-of-function phenotypes in cancer and differentiation models. This is a primary approach to test causality.
Point Mutation
Introducing point mutations in SRA RNA (e.g., at pseudouridylation sites) or in protein RNA-binding domains can dissect specific interactions without completely removing the gene. This helps distinguish binding-dependent from independent functions.
Knock-in
Knock-in of epitope-tagged SRA or SRAP allows for affinity purification and localization studies. Tagged knock-in models enable precise tracking of SRA RNA-protein complexes.
Overexpression
Overexpression of SRA or its binding partners can enhance steroid receptor activity and drive disease phenotypes, providing gain-of-function models. These models are useful for testing inhibitors of SRA-mediated interactions.
How EDITGENE Supports steroid receptor RNA activator RNA binding Research
Researchers studying steroid receptor RNA activator RNA binding-related genes often need to determine whether a candidate gene is causally involved in SRA-mediated transcriptional regulation or whether it is merely a bystander. EDITGENE provides a comprehensive suite of CRISPR services to address these questions with precision and scale.
Contact EDITGENE today to design your custom CRISPR model for steroid receptor RNA activator RNA binding research.
Frequently Asked Questions About steroid receptor RNA activator RNA binding
What is GO:0002153?
GO:0002153 is the molecular function of binding to the steroid receptor RNA activator RNA (SRA), a long non-coding RNA that enhances steroid hormone receptor transcriptional activity indirectly.
What is steroid receptor RNA activator RNA binding?
It is the function of proteins or molecules binding to SRA RNA, which acts as a coregulator of nuclear receptors without directly binding the receptor.
What genes are involved in steroid receptor RNA activator RNA binding?
Key genes include SRA1 (encoding SRA RNA), DDX5 (p68), PUS1, and steroid receptors such as ESR1, AR, and PGR.
How does SRA enhance steroid receptor activity?
SRA acts as an RNA scaffold to recruit coregulatory proteins that indirectly enhance receptor transcriptional activity, not by direct SRA-receptor binding.
What diseases are associated with SRA RNA binding?
SRA is implicated in endometrial cancer, polycystic ovary syndrome, and erythroid disorders.
What is the role of p68 in SRA function?
p68 (DDX5) binds SRA RNA and mediates CTCF transcriptional insulation, linking SRA to chromatin regulation.
How is SRA RNA modified?
SRA RNA can be pseudouridylated by hPus1p, which affects its RNA binding and activity.
Can CRISPR be used to study SRA RNA binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect SRA function.
What methods study SRA RNA-protein interactions?
RNA immunoprecipitation, EMSA, proteomics, and structural studies are commonly used.
Why is SRA important in cancer?
SRA promotes endometrial cancer progression via Wnt/β-catenin signaling, making it a potential therapeutic target.
Conclusion
GO:0002153, steroid receptor RNA activator RNA binding, represents a critical molecular function at the intersection of non-coding RNA biology and nuclear receptor signaling. Its study has revealed complex mechanisms of transcriptional regulation and its dysregulation in diseases such as endometrial cancer and PCOS. Continued research using advanced CRISPR models and integrated omics will further illuminate how SRA RNA binding shapes cellular physiology and disease.
References
- 1. Park SA et al.. 2020. Long non-coding RNA steroid receptor activator promotes the progression of endometrial cancer via Wnt/ β-catenin signaling pathway.. Int J Biol Sci 16(1):99-115 PMID: 31892849
- 2. Colley SM et al.. 2011. Steroid Receptor RNA Activator - A nuclear receptor coregulator with multiple partners: Insights and challenges.. Biochimie 93(11):1966-72 PMID: 21807064
- 3. Huet T et al.. 2014. Steroid receptor RNA activator (SRA) modification by the human pseudouridine synthase 1 (hPus1p): RNA binding, activity, and atomic model.. PLoS One 9(4):e94610 PMID: 24722331
- 4. Li Y et al.. 2019. Silencing of LncRNA steroid receptor RNA activator attenuates polycystic ovary syndrome in mice.. Biochimie 157:48-56 PMID: 30391287
- 5. Sawaengdee W et al.. 2020. Genome-Wide Transcriptional Regulation of the Long Non-coding RNA Steroid Receptor RNA Activator in Human Erythroblasts.. Front Genet 11:850 PMID: 32849830
- 6. McKay DB et al.. 2014. Structure and function of steroid receptor RNA activator protein, the proposed partner of SRA noncoding RNA.. J Mol Biol 426(8):1766-1785 PMID: 24486609
- 7. Yao H et al.. 2010. Mediation of CTCF transcriptional insulation by DEAD-box RNA-binding protein p68 and steroid receptor RNA activator SRA.. Genes Dev 24(22):2543-55 PMID: 20966046
- 8. Xu B et al.. 2004. An RNA-binding domain in the thyroid hormone receptor enhances transcriptional activation.. J Biol Chem 279(32):33051-6 PMID: 15180993
